Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own3.55% Shs Outstand113.16M Perf Week13.11%
Market Cap858.88M Forward P/E- EPS next Y-0.57 Insider Trans4.15% Shs Float108.81M Perf Month25.87%
Income-53.55M PEG- EPS next Q-0.14 Inst Own63.30% Short Float8.88% Perf Quarter29.74%
Sales42.33M P/S20.29 EPS this Y-150.13% Inst Trans-5.48% Short Ratio7.16 Perf Half Y42.94%
Book/sh0.28 P/B27.11 EPS next Y31.60% ROA-53.42% Target Price8.07 Perf Year0.40%
Cash/sh0.88 P/C8.60 EPS next 5Y- ROE-179.24% 52W Range3.86 - 9.92 Perf YTD13.11%
Dividend- P/FCF- EPS past 5Y0.00% ROI-65.21% 52W High-23.49% Beta1.51
Dividend %- Quick Ratio6.77 Sales past 5Y61.94% Gross Margin97.41% 52W Low96.63% ATR0.43
Employees152 Current Ratio6.92 Sales Q/Q803.86% Oper. Margin-126.70% RSI (14)65.78 Volatility8.11% 5.66%
OptionableYes Debt/Eq0.64 EPS Q/Q77.98% Profit Margin-126.53% Rel Volume1.05 Prev Close7.57
ShortableYes LT Debt/Eq0.64 EarningsMay 08 AMC Payout- Avg Volume1.35M Price7.59
Recom2.50 SMA2017.25% SMA5026.56% SMA20023.35% Volume1,412,140 Change0.26%
01-May-13Reiterated UBS Neutral $8 → $6.50
24-Sep-12Reiterated Barclays Overweight $8 → $10
18-Oct-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
01-Apr-11Initiated Stifel Nicolaus Buy $10
19-Oct-10Initiated JMP Securities Mkt Perform
06-Oct-10Initiated Barclays Capital Overweight $12
08-Apr-10Initiated William Blair Outperform
22-Mar-10Upgrade Brean Murray Hold → Buy $13
13-Oct-09Upgrade Wedbush Morgan Neutral → Outperform $7 → $10
29-Apr-09Upgrade Roth Capital Hold → Buy $5 → $8
21-Apr-09Initiated Wedbush Morgan Buy $7
26-Feb-09Initiated Merriman Curhan Ford Buy
11-Aug-08Downgrade Brean Murray Buy → Hold
08-Aug-08Reiterated Roth Capital Hold $6 → $6.50
17-Mar-08Reiterated Roth Capital Hold $9 → $6
17-Mar-08Reiterated Brean Murray Buy $11 → $6
12-Nov-07Reiterated Roth Capital Hold $10 → $9
11-Sep-07Initiated Morgan Joseph Sell $6
10-Aug-07Reiterated Roth Capital Hold $11 → $10
10-Aug-07Reiterated Brean Murray Buy $12 → $11
21-May-13 10:11AM  American Society Of Clinical Oncology Abstracts Point To Potential Profits at Seeking Alpha
09:00AM  Baxter Receives Marketing Authorization for HyQvia in European Union Business Wire
18-May-13 08:15AM  3 Humongous Health-Care Stocks This Week at Motley Fool
17-May-13 01:33PM  Nasdaq stocks posting largest percentage increases AP
10:28AM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh EDGAR Online
16-May-13 07:34PM  Cancer Drug Drama Rocks 2 Biotech Stocks at Motley Fool +18.40%
06:03PM  Nasdaq stocks posting largest percentage increases AP
04:41PM  Halozyme rises on pancreatic cancer drug study AP
04:15PM  Halozyme rises on prostate cancer drug study AP
02:25PM  Little-noticed firm makes a splash with pancreatic cancer treatment at MarketWatch
02:09PM  [video] Biotech's Next Big Thing ASCO II at TheStreet
02:09PM  [video] Biotech's Next Big Thing -- ASCO II at TheStreet
01:41PM  Why Halozyme Therapeutics Shares Soared at Motley Fool
01:29PM  Nasdaq stocks posting largest percentage increases AP
15-May-13 06:24PM  InPlay: Halozyme Therapeutics to present new data on PEGPH20 in pancreatic cancer at American Society of Clinical Oncology Annual Meeting Briefing.com
06:05PM  Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting PR Newswire
06:00PM  10 ASCO '13 Abstracts You Can Read Right Now at TheStreet
01:04PM  HALOZYME THERAPEUTICS INC Financials EDGAR Online Financials
02:13AM  Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
10-May-13 03:56PM  Short Interest Increases 11.2% For HALO at TheStreet +6.99%
08-May-13 07:00PM  Halozyme Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
06:55PM  Halozyme Therapeutics Earnings: Heres Why Investors are Ambivalent Now at Wall St. Cheat Sheet
04:08PM  InPlay: Halozyme Therapeutics misses by $0.02, beats on revs Briefing.com
04:05PM  Halozyme Reports First Quarter 2013 Financial Results PR Newswire
09:17AM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q1 2013 Halozyme Therapeutics, Inc. Earnings Release - After Market Close CCBN
07-May-13 04:15PM  Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference PR Newswire
06-May-13 12:13PM  Forbes Earnings Preview: Halozyme Therapeutics, Inc. at Forbes
03-May-13 09:10PM  Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue at Seeking Alpha
02-May-13 01:30PM  ViroPharma Reports Loss in 1Q Zacks
01-May-13 04:15PM  Halozyme to Host First Quarter 2013 Financial Results Conference Call PR Newswire
29-Apr-13 11:35AM  Large Market Opportunity in Hepatitis C from a Volume Perspective: Brian Skorney Discusses Pockets in the Hepatitis C Space Where Companies Other Than Gilead (GILD) Will See Value Wall Street Transcript
24-Apr-13 04:16PM  Renewed Buying Interest In Halozyme After Phase II Initiation at Seeking Alpha
23-Apr-13 03:29PM  4 Under-$10 Stocks Making Big Moves at TheStreet +8.46%
11:49AM  HALO Makes Bullish Cross Above Critical Moving Average at TheStreet
08:00AM  Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer PR Newswire
08-Apr-13 07:40AM  Last Week's Best- And Worst-Performing Medical Stocks at Forbes
05-Apr-13 05:52PM  3 Horrendous Health-Care Stocks This Week at Motley Fool
03-Apr-13 10:27AM  ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity at Seeking Alpha
29-Mar-13 01:04PM  HALOZYME THERAPEUTICS INC Financials EDGAR Online Financials
28-Mar-13 04:19PM  Halozyme Therapeutics Names Matt Posard to Board of Directors PR Newswire
09:37AM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
26-Mar-13 07:58PM  Nasdaq stocks posting largest percentage decreases AP
01:18PM  Nasdaq stocks posting largest percentage decreases AP
09:09AM  Halozyme Rallies On Success In Europe, US Next Target at Seeking Alpha
25-Mar-13 01:34PM  Whoa! These Stocks Outpaced the Dow at Motley Fool -12.17%
01:27PM  Nasdaq stocks posting largest percentage decreases AP
08:25AM  Last Week's Biotech Movers: Are Any A Buy? at Seeking Alpha
24-Mar-13 08:00AM  Last Week's Best- And Worst-Performing Medical Stocks at Forbes
23-Mar-13 12:00PM  This Week in Biotech at Motley Fool
22-Mar-13 06:04PM  Nasdaq stocks posting largest percentage increases AP +30.93%
02:37PM  BRIEF-Halozyme Therapeutics shares up 27 pct in heavy volume at Reuters
01:38PM  Why Halozyme Therapeutics Shares Skyrocketed at Motley Fool
01:17PM  Nasdaq stocks posting largest percentage increases AP
11:30AM  Halozyme Is Attractive Again After EU Opinion On HyQvia at Seeking Alpha
11:16AM  Biogen, Baxter, Sanofi, Gilead Win EU Endorsements at Investor's Business Daily
08:32AM  InPlay: Halozyme Therapeutics and Baxter (BAX) announce positive opinion for HyQvia for treatment of primary and secondary Immunodeficiencies in the European Union Briefing.com
08:32AM  Baxter, Halozyme announce positive CHMP opinion for HyQvia at theflyonthewall.com
08:31AM  Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union PR Newswire
12-Mar-13 08:31PM  New Star Analyst Rankings for Halozyme Therapeutics, Inc. StarMine -5.79%
06:00PM  Halozyme Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2013 04:15 PM at Seeking Alpha
11-Mar-13 08:20AM  New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012 Marketwire
05-Mar-13 04:15PM  Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference PR Newswire
01-Mar-13 06:13AM  HALOZYME THERAPEUTICS INC Files SEC form 10-K, Annual Report EDGAR Online
28-Feb-13 04:07PM  ViroPharma Tops on All Fronts Zacks
27-Feb-13 06:02PM  Nasdaq stocks posting largest percentage decreases AP
01:17PM  Nasdaq stocks posting largest percentage decreases AP
26-Feb-13 07:43PM  New Star Analyst Rankings for Halozyme Therapeutics, Inc. StarMine -9.62%
06:15PM  Nasdaq stocks posting largest percentage decreases AP
01:20PM  Nasdaq stocks posting largest percentage decreases AP
25-Feb-13 08:01PM  Halozyme Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
05:30PM  Halozyme Therapeutics Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet
04:17PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:11PM  InPlay: Halozyme Therapeutics beats by $0.12, beats on revs; co reaffirms cash burn outlook Briefing.com
04:05PM  Halozyme Reports Fourth Quarter and Year End 2012 Financial Results PR Newswire
07:07AM  Q4 2012 Halozyme Therapeutics, Inc. Earnings Release - Before Market Open CCBN
20-Feb-13 11:38AM  Forbes Earnings Preview: Halozyme Therapeutics at Forbes
19-Feb-13 04:30PM  Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call PR Newswire
13-Feb-13 02:53PM  Is Now The Time To Jump Into Halozyme? at Seeking Alpha
07-Feb-13 08:20AM  FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High Marketwire
05-Feb-13 02:43AM  Insider Buying Trends: Are These Cash Rich Companies Ready To Rally? at Seeking Alpha
01-Feb-13 05:34PM  3 Horrendous Health-Care Stocks This Week at Motley Fool
09:59AM  Abercrombie & Fitch to Benefit From Easier Comps and 3 Stock Analyses to Track at Wall St. Cheat Sheet
31-Jan-13 06:05PM  Nasdaq stocks posting largest percentage decreases AP -5.64%
05:04PM  Halozyme falls after analyst downgrade AP
04:38PM  A Broken HALO for Wall Street? at Motley Fool
03:18PM  Halozyme falls after analyst downgrade AP
01:16PM  Nasdaq stocks posting largest percentage decreases AP
11:30AM  InPlay: Halozyme Therapeutics seeing continued weakness following analyst downgrade yesterday afternoon Briefing.com
30-Jan-13 11:14AM  Largest option buying in equities so far optionMONSTER -11.71%
24-Jan-13 01:21PM  Baxter's Earnings Call Reveals Good News For Halozyme at Seeking Alpha
23-Jan-13 05:58PM  Foolish Preview: Baxter Earnings at Motley Fool
17-Jan-13 01:41PM  Synageva director bought shares for trust at MarketWatch
16-Jan-13 12:28AM  4 Rallying Biotech Stocks Being Snapped By Insiders at Seeking Alpha
15-Jan-13 06:02PM  Nasdaq stocks posting largest percentage increases AP
01:37PM  Nasdaq stocks posting largest percentage increases AP
14-Jan-13 06:03PM  Nasdaq stocks posting largest percentage increases AP +15.67%
04:02PM  Halozyme climbs as analyst upgrades stock AP
03:52PM  Is Halozyme Back? at Motley Fool
03:16PM  The Upward Climb Of Halozyme Therapeutics at Seeking Alpha
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frost Gregory IanCEO, PresidentFeb 02Option Exercise0.0016,04903,571,380Feb 05 08:23 PM
Shaffer James PVP & Chief Commercial OfficerFeb 02Option Exercise0.0011,232037,532Feb 05 08:21 PM
Shepard H. MichaelVP, Chief Scientific OfficerFeb 02Option Exercise0.0011,798023,198Feb 05 08:20 PM
GUSTAFSON KURT AVice President and CFOFeb 02Option Exercise0.0012,467035,667Feb 05 08:19 PM
LIU JEAN IVP & General CounselFeb 02Option Exercise0.007,82707,827Feb 05 08:17 PM
Engler RobertDirectorNov 29Buy5.5715,00083,550165,000Nov 29 07:15 PM
Shaffer James PVP & Chief Commercial OfficerNov 14Buy5.2220,000104,40026,300Nov 14 07:06 PM
FALBERG KATHRYN EDirectorNov 13Buy5.2150,000260,500160,000Nov 14 07:12 PM
Kelley Kenneth JDirectorAug 27Buy5.7020,000113,974150,000Aug 28 06:22 PM
Frost Gregory IanCEO, PresidentAug 13Buy5.502,00011,0003,555,331Aug 14 08:17 PM
KIRK RANDAL JDirectorJun 05Buy7.485,46340,863331,395Jun 05 05:41 PM
KIRK RANDAL JDirectorJun 04Buy7.3789,646660,691328,663Jun 05 05:41 PM
KIRK RANDAL JDirectorJun 01Buy7.3999,080732,201283,840Jun 05 05:41 PM